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Drug efflux protein complexes confer multidrug resistance on bacteria by transporting a
wide spectrum of structurally diverse antibiotics. Moreover, organisms can only acquire
resistance in the presence of an active efflux pump. The substrate range of drug
efflux pumps is not limited to antibiotics, but it also includes toxins, dyes, detergents,
lipids, and molecules involved in quorum sensing; hence efflux pumps are also
associated with virulence and biofilm formation. Inhibitors of efflux pumps are therefore
attractive compounds to reverse multidrug resistance and to prevent the development of
resistance in clinically relevant bacterial pathogens. Recent successes on the structure
determination and functional analysis of the AcrB and MexB components of the
AcrAB-TolC and MexAB-OprM drug efflux systems as well as the structure of the fully
assembled, functional triparted AcrAB-TolC complex significantly contributed to our
understanding of the mechanism of substrate transport and the options for inhibition
of efflux. These data, combined with the well-developed methodologies for measuring
efflux pump inhibition, could allow the rational design, and subsequent experimental
verification of potential efflux pump inhibitors (EPIs). In this review we will explore how the
available biochemical and structural information can be translated into the discovery and
development of new compounds that could reverse drug resistance in Gram-negative
pathogens. The current literature on EPIs will also be analyzed and the reasons why no
compounds have yet progressed into clinical use will be explored.
Keywords: multidrug resistance, drug efflux, efflux pump inhibitor, Gram-negative, pathogen, antimicrobial
resistance
Introduction
Over the last two decades there has been a dramatic surge in the number of multidrug resistant
bacteria, yet paradoxically the number of pharmaceutical companies developing new antimicro-
bial agents has dwindled during this same period. As a result, antibiotic resistance is now one of
the world’s most pressing health problems (WHO, 2014). Therefore, new treatments to combat
drug resistant bacteria are urgently needed if we do not want to return to the high mortality rates
associated with infections during the pre-antibiotic era (Bush et al., 2011; WHO, 2014).
Hospital acquired pathogens such as Staphylococcus aureus,Klebsiella pneumonia,Acinetobacter
baumannii, and Pseudomonas aeruginosa which can cause life-threatening infections display high
levels of antibiotic resistance (Poole, 2011; Bassetti et al., 2013). Resistance of K. pneumonia
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to carbapenems, the last resort treatment for severe infections, of
up to 54% of cases were reported (WHO, 2014).
Recently a few new antibiotics have been approved for the
use against Gram-positive organisms (Butler and Cooper, 2011).
However, infections caused by Gram-negative pathogens proved
much harder to treat due to the very high intrinsic drug resis-
tance displayed by Gram-negative organisms. This intrinsic drug
resistance is due to presence of an outer membrane which acts
as a permeability barrier and by the expression of drug eﬄux
pumps.
Drug eﬄux pumps are protein complexes which reside in
the membrane and remove antimicrobials and toxins, thereby
lowering their concentration inside the cell to sub-toxic levels
(Poole, 2004, 2005; Piddock, 2006a; Nikaido and Pages, 2012).
These proteins recognize and expel a wide range of struc-
turally diverse antibiotics with diﬀerent mechanisms and sites
of action. The clinical implication of this substrate promis-
cuity is the development of multidrug resistance where a
pathogen displays resistance against multiple classes of antimi-
crobials.
Apart from antibiotics drug eﬄux proteins can also trans-
port antiseptics and disinfectants (Chuanchuen et al., 2003;
Sanchez et al., 2005; Mima et al., 2007; Pumbwe et al., 2007),
detergents (including naturally occurring bile salts; Rosenberg
et al., 2003; Lin et al., 2005), fatty acids (Lee and Shafer, 1999;
Lennen et al., 2013), heavy metals (Silver and Phung, 1996;
Walmsley and Rosen, 2009), solvents (White et al., 1997; Ramos
et al., 2002; Segura et al., 2012), and virulence factors (Piddock,
2006b). Therefore, drug eﬄux pumps are also important con-
stituents of bacterial pathogenesis, virulence, and bioﬁlm forma-
tion (Hirakata et al., 2002, 2009; Piddock, 2006b; Ikonomidis
et al., 2008; Martinez et al., 2009; Baugh et al., 2012, 2014; Amaral
et al., 2014). In addition, micro-organisms can only acquire resis-
tance in the presence of drug eﬄux pumps (Lomovskaya and
Bostian, 2006; Ricci et al., 2006; Zhang et al., 2011; Piddock,
2014) as these non-speciﬁc pumps remove most compounds until
the organism has had time to acquire resistance to an antibiotic
through more speciﬁc adaptive mechanisms.
Despite their crucial role in bacterial pathogenesis and mul-
tidrug resistance there are currently no inhibitors for drug eﬄux
pumps in clinical use. Therefore drug eﬄux pumps are attractive
targets for inhibition. Eﬄux pump inhibitors (EPIs) will (a) syn-
ergise with currently used antibiotics, (b) restore the eﬃcacy of
antibiotics to which resistance has arisen, (c) reduce the incidence
of emergence of drug-resistant pathogens, (d) reduce the ability
of pathogens to infect the host as the inhibition of eﬄux atten-
uates the bacterium, and (e) prevent the development of highly
drug resistant bioﬁlms
Drug Efflux Pumps in Gram-Negative
Bacteria
Gram-negative pathogens rely on tripartite protein assemblies
that span their double membrane to pump antibiotics from
the cell. The tripartite complex consists of an inner membrane
protein (IMP) of the resistance nodulation cell division (RND)
family, an outer-membrane protein (OMP), and a periplas-
mic membrane fusion protein (MFP) which connect the other
two proteins (Figure 1). The inner-membrane protein cataly-
ses drug/H+ antiport and is the part of the complex responsi-
ble for drug selectivity. The best studied tripartite drug eﬄux
complexes are the AcrA-AcrB-TolC and MexA-MexB-OprM
transporters from Escherichia coli and P. aeruginosa, respec-
tively, (Du et al., 2013). The IMPs AcrB and MexB share
86% similarity and MexB can functionally substitute for AcrB
(Krishnamoorthy et al., 2008; Welch et al., 2010). The asym-
metric structure of the AcrB homotrimer and subsequent bio-
chemical analysis revealed a functional rotating mechanism
where the monomers cycle through the diﬀerent states loose
(L), tight (T), and open (O; Murakami et al., 2006; Seeger
et al., 2006, 2008b). IMPs such as AcrB consist of a trans-
membrane domain and periplasmic domain. The drug eﬄux
pathway from the periplasm/outer membrane leaﬂet through the
periplasmic domain of AcrB has been the focus of many stud-
ies and are now relatively well-understood (Murakami, 2008;
Seeger et al., 2008a; Eicher et al., 2009; Misra and Bavro,
2009; Nikaido and Takatsuka, 2009; Pos, 2009; Nikaido, 2011;
Nikaido and Pages, 2012; Ruggerone et al., 2013a,b). Recently,
it was also found that mutations at the cytoplasmic face of
MexB aﬀected transport of drugs with targets inside the cell
(Ohene-Agyei et al., 2012). This raises the possibility that sim-
ilar to the cytoplasmic pathway for Cu(II) in CusA (Delmar
et al., 2014), MexB might also have the ability to remove
antibiotics from the inner membrane leaﬂet/cytoplasm (Ohene-
Agyei et al., 2012). Targeted geometric simulations showed that
such a cytoplasmic pathway could be possible even though it
would not necessarily out-compete the periplasmic channel for
FIGURE 1 | Schematic representation of a tripartite drug efflux
complex. (A) The complex consists of three proteins which span the
inner-membrane (CM), the outer membrane (OM), and the periplasmic space.
The inner-membrane protein (IMP), e.g., AcrB or MexB is responsible for
substrate specificity and catalyzes pH dependent drug transport. Examples
of the outer membrane protein (OMP) are TolC or OprM. The periplasmic
membrane fusion protein (MFP), e.g., AcrA or MexA connects the IMP and the
OMP. (B) Structures of the individual components of the efflux pump. The
MexA (pdb: 2V4D), MexB (pdb: 2V50), and OprM (pdb: 1WP1) proteins from
Pseudomonas aeruginosa are given as examples.
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drug binding and transport (Phillips and Gnanakaran, 2015).
Biochemical and structural analysis revealed that the perplas-
mic binding site in AcrB contains a shallow (proximal) and
deep (distal) binding pocket separated by a switch loop (G-
loop) consisting of residues 614–621 (Nakashima et al., 2011;
Eicher et al., 2012; Cha et al., 2014). Conformational ﬂexibil-
ity in this loop is necessary to move the substrate along the
extended binding site. Mutations that change the small glycine
residues in this loop to bulkier residues aﬀects transport of
larger macrolide antibiotics such as erythromycin while the activ-
ity toward smaller compounds such as novobiocin, ethidium,
and chloramphenicol remained unaﬀected (Bohnert et al., 2008;
Wehmeier et al., 2009; Nakashima et al., 2011, 2013; Eicher
et al., 2012). Therefore, EPIs would most eﬀectively inhibit the
eﬄux of diﬀerent antibiotics by interaction with the switch
loop.
Due to the complexity of these macromolecular structures
progress on elucidating their assembly and structure was slow.
Only very recently Du et al. (2014) used a creative approach of
genetic fusion proteins to solve the ﬁrst structure of a partially
active, fully assembled, tripartite pump in the presence of a mod-
ulatory partner. This structure of AcrA–AcrB–AcrZ–TolC shed
light on long disputed subunit stoichiometries and revealed that
the complex assembles in a 3 : 6 : 3 ratio of AcrB : AcrA : TolC
with one monomer of AcrZ bound to each subunit of AcrB. The
role of the small protein AcrZ is not clear, however, as it alters
the substrate speciﬁcity of AcrB (Hobbs et al., 2012) it most likely
plays a modulatory role.
The structural similarity between transporters from diﬀerent
Gram-negative organisms means that EPIs developed against,
e.g., the AcrA–AcrB–TolC eﬄux pump from E. coli would most
likely be eﬀective against other pathogens also. Our current
understanding of the structure and function of RNDeﬄux pumps
from Gram-negative bacteria could therefore provide the basis
for the informed and eﬃcient design of inhibitors against these
protein complexes.
Approaches to Inhibit Drug Efflux
The expression, function and assembly of drug eﬄux pumps of
the RND class can be targeted in several ways (Figure 2).
Targeting the Regulatory Network that
Controls the Expression of Efflux Pumps as
Levels of Pump Expression are Controlled
by Activators and Repressors
Some progress has already been made in understanding the
regulation of eﬄux pump expression, e.g., expression of AcrB
from Salmonella enterica (Blair et al., 2014) and the regulation
of eﬄux pump expression in P. aeruginosa (Wilke et al., 2008;
Starr et al., 2012; Hay et al., 2013; Purssell and Poole, 2013;
Lau et al., 2014). The expression levels of eﬄux pumps could
be measured by real time PCR or with green ﬂuorescent pro-
tein reporter fusions (Bumann and Valdivia, 2007; Ricci et al.,
2012). Both these methods are amenable to high-throughput
processing.
FIGURE 2 | Inhibition strategies. Schematic representation of a tripartite
drug efflux complex in complex with a small protein such as AcrZ. The
possible approaches of inhibiting drug efflux are depicted.
Changing the Molecular Design of Old
Antibiotics so that they are No Longer
Recognized and Transported by the Efflux
Pump
Given the wide range of compounds which could be recog-
nized by drug eﬄux transporters, the plasticity in the binding
sites, and the redundancy in aromatic residues in the bind-
ing pocket which could stabilize substrate binding (Du et al.,
2013), this approach might prove a daunting task. In addition,
altering the chemical structure of the antibiotic might render it
less eﬃcient against its intended cellular target. However, some
progress has been made in this regard for a diﬀerent class of
drug eﬄux protein, the ATP binding cassette transporter, human
P-glycoprotein where the substrate taxol was chemically modi-
ﬁed so that P-glycoprotein no longer recognized it. This allowed
the drug to cross the blood brain barrier and access its target
receptor without being removed by P-glycoprotein (Rice et al.,
2005).
Preventing the Assembly of the Efflux Pump
Components into a Functional Tripartite
Pump by Targeting Protein–Protein
Interfaces
This is a very promising approach which is still under-developed
due to the lack of information of how tripartite pumps assemble.
However, Tikhonova et al. (2011) showed that designed ankyrin
repeat proteins (DARPins) could inhibit AcrAB-TolC function
by inhibiting the interaction between AcrA and AcrB. The recent
structure of a complete tripartite drug eﬄux pump and the infor-
mation gained from that also opens up exciting new possibilities
(Du et al., 2014). The interaction of puriﬁed protein components
of the pump with each other can be measured with surface plas-
mon resonance (SPR). The ability of eﬄux pumps to assemble
in vivo can be measured by cross-linking in whole cells with
subsequent co-purifying of the pump components (Welch et al.,
2010).
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Disrupting the Interaction Between AcrB
and AcrZ
The exact role of AcrZ in drug eﬄux is still ill-deﬁned. However,
as AcrA–AcrB–TolC has a diminished ability to confer resis-
tance to some drugs in the absence of AcrZ (Hobbs et al., 2012),
this approach could be promising for restoring sensitivity to
some antibiotics. Homologs of AcrZ are found in most Gram-
negative bacteria, therefore the modulatory eﬀect of RND class
of transporters by small proteins is probably a widely conserved
occurrence. The interaction between the IMP and a small protein
such as AcrZ could be measured with SPR or with cross-linking
in cells as mentioned above.
Directly Blocking the IMP with a High Affinity
Competing Substrate or Trapping the IMP in
an Inactive Conformation
The recent crystal structure of AcrB and MexB bound to an
inhibitor (Nakashima et al., 2013) and the advances in our under-
standing of how drugs are bound makes this option very attrac-
tive (see Eﬄux Pump Inhibitors Against Gram-Negative Bacteria
Identiﬁed So Far). The ability of compounds to inhibit antibi-
otic eﬄux can be measured using drug accumulation or drug
eﬄux assays (see Inhibition of Substrate Transport), while direct
interaction between the test compound and the IMP component
could be determined with isothermal calorimetry (ITC) or SPR
(Tikhonova et al., 2011).
Blocking the Exit Duct (the OMP)
A set of indole derivatives was designed based on the structure of
TolC. These compounds were able to synergise with antibiotics
and were reported to act on TolC speciﬁcally, presuming by pre-
venting opening of the channel (Zeng et al., 2010). In addition,
TolC from E. coli contains an electronegative entrance formed
by an aspartate ring which is widely conserved throughout the
TolC family and which could be a target for blocking by large
cations (Andersen et al., 2002). The biggest challenge with this
approach is achieving selectivity to the bacterial pores. Blocking
of the OMP could be detected by inhibition of antibiotic eﬄux
through the tripartite pump or by disruption of TolC-mediated
conductance.
Depleting the IMP From the Energy Needed
to Drive the Drug/H+ Antiport Reaction
The proton motive force (pmf) can easily be disrupted by the use
of ionophores or compounds that disrupt the membrane integrity
in one way or another. However, these eﬀects are mostly not spe-
ciﬁc for bacterial membranes and hence compounds that act in
this way would be cytotoxic to the host cells too. The magnitude
of the pmf and the eﬀect of test compounds on these could be
determined by the use of ﬂuorescent probes speciﬁc for the 
or pH components of the pmf (Venter et al., 2003).
How Could EPIs be Identified?
Signiﬁcant eﬀort went into the biochemical and structural char-
acterization of drug eﬄux proteins from Gram-negative bacteria.
Recent successes such as the structural determination of an
intact pump and of IMPs bound to an inhibitor (Nakashima
et al., 2013; Du et al., 2014) oﬀer a solid platform for the
rational design of EPIs using quantitative structure-activity rela-
tionship data (Ruggerone et al., 2013a; Wong et al., 2014;
Figure 3).
Recently we used in silico screening to identify com-
pounds which would bind to AcrB with reasonable aﬃn-
ity. Of the roughly ﬁfty compounds docked, six compounds
were selected for further study. The docking allowed us to
provide an order of eﬃciency of the compounds as poten-
tial EPIs. The biochemical data compared well with the pre-
dictions from the docking showing that in silico screen-
ing could be used as an eﬀective screening tool to limit
the amount of experiments needed or save on precious and
hard earned puriﬁed natural products (Ohene-Agyei et al.,
2014).
Another approach with good scope for success is investi-
gating compounds puriﬁed from plants (Tegos et al., 2002).
Traditional peoples have used plants to treat infections for 100s
if not 1000s of years. In western medicine, plants are thus
far an under-utilized source of chemical components in the
treatment of infectious disease. Resistance to medicinal plant
extracts have not been described yet and extracts of herbal
medicines have been shown to potentiate antibiotic action in
resistant pathogens (Garvey et al., 2011; Ohene-Agyei et al.,
2014). Therefore, it is likely that as well as antibacterial chemicals,
plants may also produce compounds that circumvent eﬄux-
mediated resistance. Hence, activity guided fractionation can be
used to identify the bio-active phytochemicals in plant extracts
with EPI activity against Gram-negative organisms (Garvey et al.,
2011).
Tools for Studying Efflux Pump
Inhibitors
The most signiﬁcant problem in current screening campaigns
for EPIs is that in many cases the synergism observed could
be attributed to non-speciﬁc damage to the bacterial mem-
brane. This would be a strong indicator the compound would
have similar activity against mammalian cells and hence would
be cytotoxic. This was clearly the case for the EPI Phe-
Arg-β-naphthylamide (PAβN; Marquez, 2005; Lomovskaya and
Zgurskaya, 2011).
Therefore, there need to be a thorough investigation in order
to verify true EPI action (Figure 3). Compounds that perme-
abilise the membrane of Gram-negative organisms will always
show synergism with antibiotics. For example, the modulatory
eﬀect of α-tocopherol in multidrug resistant Gram-negative bac-
teria such as P. aeruginosa and E. coli could most probably
be attributed to the eﬀects of α-tocopherol on the membrane
(Andrade et al., 2014). It is therefore important that potential
inhibitors are not only identiﬁed on their synergism with antibi-
otics, but that a subsequent biochemical assays are performed to
determine that the compounds are truly acting by inhibiting drug
eﬄux.
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FIGURE 3 | The tools for EPI discovery.
In order to qualify as an EPI a compound must be able to
satisfy the following criteria as stipulated by Lomovskaya et al.
(2001).
(a) It must potentiate the activity of antibiotics to which a strain
has developed resistance as a result of the expression of a drug
eﬄux pump.
(b) It should not have an eﬀect on sensitive strains which lack the
drug eﬄux pump.
(c) It must not reduce the MIC of antibiotics which are not
eﬄuxed.
(d) It must increase the level of accumulation and decrease the
level of extrusion of compounds which are substrates of the
eﬄux pump.
(e) It must not permeabilise the outer membrane.
(f) It must not aﬀect the proton gradient across the inner mem-
brane.
All the above criteria can be addressed with well-
developed techniques as outlined below and in Figure 3,
which would be amenable to scale-down for high throughput
analysis.
Measuring Synergism
The ﬁrst thing to do is to determine the MIC of the test com-
pound using standard broth dilution assays (Lomovskaya et al.,
2001; Welch et al., 2010; Ohene-Agyei et al., 2012, 2014). Ideally
the compound should not be toxic to bacterial cells or only toxic
at high concentrations. This would prevent resistance against the
test compound from developing very quickly. The compound
would then be used at concentrations below its MIC (usually
4× lower than the MIC) to test for synergism with antibiotics
to which the organism has developed resistance. Synergism is
best studied using checkerboard assays. These assays could be
performed in a 96-well plate format with the antibiotic serially
diluted along the ordinate and the test compound serially diluted
along the abscissa (Lomovskaya et al., 2001; Orhan et al., 2005;
Ohene-Agyei et al., 2014). The MIC of the antibiotic is deter-
mined in the presence of a range of diﬀerent concentrations of the
compound. Antibiotic-EPI interactions are subsequently classi-
ﬁed on the basis of fractional inhibitory concentration (FIC). The
FIC index is the sum of the FIC of each of the antibiotics, which in
turn is deﬁned as the MIC of the antibiotic when used in combi-
nation divided by the MIC of the antibiotic when used alone. The
combination is considered synergistic when the FIC is ≤0.5,
indiﬀerent when the FIC is >0.5 to <2, and antagonistic when
the FIC is ≥2.
Ensuring the Compound has no Effect on
Strains Which Lack the Drug Efflux Pump
An eﬀective way of testing the eﬀect of a compound on eﬄux
pump mediated resistance is to use a wild-type antimicrobial
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resistant strain and a sensitive strain with a genomic deletion of
the IMP. Checkerboard assays can be performed on the wild type
strain to determine if MIC drop toward that of sensitive strain.
Conversely the compound should not have an eﬀect on the MIC
of the sensitive strain.
However, it is important not to use a strain with a TolC dele-
tion. TolC is a multi-functional protein that operates with the
majority of MFP-dependent transporters encoded in the genome
of E. coli (Zgurskaya et al., 2011). Results from TolC minus cells
would therefore be complicated by eﬀects which are not related
to active drug eﬄux (Ohene-Agyei et al., 2014).
Inhibition of Substrate Transport
The ability of a potential EPI to inhibit substrate transport
in a drug eﬄux pump can be measured by performing sub-
strate accumulation assays or by measuring substrate eﬄux
in the absence/presence of the putative EPI. Many ﬂuorescent
compounds are also substrates for drug eﬄux pumps. If these
compounds undergo a change in ﬂuorescence when bound to
DNA/membrane lipids they can be used to measure the eﬄux
activity of drug transporters. Many ﬂuorescent compounds fulﬁll
this role and are frequently used to measure drug eﬄux; exam-
ples are Hoechst 33342, berberine, ethidium bromide, TMA-DPH
[1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-
toluenesulfonate], N-phenylnaphthylamine and Nile Red which
display enhanced ﬂuorescence intensity when accumulated inside
the cell or doxorubicin and rhodamine 6G for which accu-
mulation inside cells results in quenching of the ﬂuorescence
signal (Lee et al., 2001; Lomovskaya et al., 2001; Seeger et al.,
2008a,b; Ohene-Agyei et al., 2012, 2014; Cha et al., 2014). In
drug accumulation assays the diﬀerence in rate of accumu-
lation of the ﬂuorescent compound between cells with and
without an active eﬄux pump are used as an indication of
eﬄux, since eﬄux will result in lower accumulation of com-
pound. In drug eﬄux assays, the de-energized cells are pre-
loaded with the ﬂuorescent compound and then energized by
the addition of glucose to catalyze drug eﬄux (observed as a
drop in ﬂuorescence). Drug inﬂux assays are more straight-
forward and much quicker to perform than drug-eﬄux assays
as de-energization and pre-loading can be time consuming.
In addition, all the samples must be pre-loaded to the same
level of ﬂuorescence to avoid diﬀerences in eﬄux rate as
a result of diﬀerences in the concentration of drug inside
the cell. The main drawback of using ﬂuorescent compounds
to measure the eﬀect of an EPI on drug eﬄux is that the
potential EPI could be highly colored or ﬂuorescent itself
and thus interfere with the measurement. Recently, Bohnert
et al. (2010) developed a method using Nile Red for eﬄux
which are compatible with highly colored or ﬂuorescent com-
pounds.
Testing of Outer Membrane Permeabilization
The most eﬀective method to measure outer membrane perme-
abilization is the nitroceﬁn hydrolysis method. Nitroceﬁn is a
chromogenic β-lactam which changes from yellow (∼380 nm)
to red (∼490 nm) when it is hydrolyzed by the periplasmic
β-lactamase, hence nitroceﬁn hydrolysis can be followed by
measuring the absorbance at 490 nm. If the test compound
permeabilises the outer membrane, nitroceﬁn will diﬀuse more
quickly over the membrane and hence the rate of nitroceﬁn
hydrolysis will increase as a result (Lomovskaya et al., 2001;
Ohene-Agyei et al., 2014). It is important to perform these essays
in the presence of the ionophore CCCP to de-energize cells and
prevent nictroceﬁn eﬄux.
Testing of Inner Membrane Permeabilization
Several methods exist to measure permeabilization of the inner-
membrane. ADNA stain which does not penetrate themembrane
of intact bacterial cells and which will undergo an increase
in ﬂuorescence quantum yield when bound to DNA such as
propdium iodide or SYTOX Green could be used (Roth et al.,
1997; Nakashima et al., 2011). SYTOX Green would be preferred
for its sensitivity as it undergoes a >500-fold enhancement in
ﬂuorescence emission when bound to DNA.
Other methods to measure the intactness of the bacterial
inner membrane involve the use or measurement of the pmf
in E. coli. Opperman et al. (2014), employed an assay based on
the uptake of [methyl-3H]β-D-thiogalactopyranoside ([3H]TMG)
by the LacY permease. The activity of the lactose permease
is dependent on the pmf as it catalysis substrate/H+ symport.
Lomovskaya et al. (2001) probed the intracellular pH of E. coli
cells by measuring the nuclear magnetic resonance (NMR) of
the 31P in the inner-membrane. Although both these two meth-
ods are eﬀective they are quite time consuming and require
access to specialist equipment. The magnitude of the individ-
ual components of the pmf can be measured directly by a
simple ﬂuorescence assay utilizing the ﬂuorescent membrane
potential probe 3,3′-diethyloxacarbocyanine iodide (DIOC2(3);
Venter et al., 2003). Moreover, the DIOC2(3) assay can eas-
ily be adapted to 96-well format for the quick analysis of
test compounds on the inner membrane in high-throughput
screening.
Use of a Non-Substrate
Another way of ruling out false positives and establishing that
compounds do not act non-speciﬁcally is to measure the eﬀect of
the test compound on an antibiotic which is not an eﬄux pump
substrate. For example our group used rifampicin, which is not
transported by the AcrAB-TolC drug eﬄux pump from E. coli
(Ohene-Agyei et al., 2014). The test compounds should not lower
the MIC of rifampicin. Any reduction in the MIC of rifampicin
would indicate that the compound does not potentiate antibiotic
action by inhibition of eﬄux, but acts by indirect means such as
permeabilization of the membrane.
EPIs Against Gram-Negative Bacteria
Identified so Far
The ﬁrst EPI to be identiﬁed against RND pumps in Gram-
negative bacteria was the peptidomimetic PAβN, originally
referred to as MC-2077110. PAβN was identiﬁed in a screen
for levoﬂoxacin potentiators against resistant P. aeruginosa.
Unfortunately, in addition to eﬄux pump inhibition it also
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TABLE 1 | Efflux pump inhibitors (EPIs) against Gram-negative pathogens.
Compound Source Protein/
Organism
Actions1 Essays performed Reference
Synthetic Compounds
Phe-Arg-
β-naphthylamide (PAβN;
MC-207,110)
Synthetic MexAB-OprM,
MexCD-OprJ,
MexEF-OprN
(Pseudomonas
aeruginosa)
Synergise with
fluoroquinolones
Antibacterial
Synergism
Substrate accumulation
Inhibition of efflux
Effect on
outer-membrane
Lomovskaya et al.
(2001)
7-nitro-8-methyl-4-[2′-
(piperidino)ethyl]
aminoquinoline
Alkylamino-quinolines AcrAB-TolC
(Enterobacter
aerogenes)
Reduced MIC of Cam, Nor,
and Tet
Increased Cam uptake
Antibacterial
Synergism
Substrate accumulation
Mallea et al. (2003)
2,8-dimethyl-4-(2′-
pyrrolidinoethyl)-
oxyquinoline
Alkoxy-quinoline
derivative
E. aerogenes
Klebsiella
pneumonia
Reduced MIC of Nor, Tet,
Cam
Substrate accumulation
Effect on membrane
Chevalier et al. (2004)
1-(1-Naphthylmethyl)-
piperazine
(NMP)
Synthetic AcrAB, AcrEF
(Escherichia coli)
Reduction in MICs of Lev,
Oxa, Rif, Cam, Clr
Increased accumulation of
ethidium
Antibacterial
Substrate accumulation
Kern et al. (2006)
New chloroquinoline
derivatives
Fluoroquinolones AcrAB-TolC
(E. aerogenes)
Reduced MIC of Cam Antibacterial
Substrate accumulation
Ghisalberti et al. (2006)
3-amino-6-carboxyl-
indole,
3-nitro-6-amino-indole
Designed and
synthesized based on
TolC structure
AcrAB-TolC
(E. coli)
Reduced MIC of cam, tet,
ery, and cip
Antibacterial
Synergism
Zeng et al. (2010)
4-(3-
morpholinopropylamino)-
quinazoline
4-alkylaminoquinazoline
derivatives
AcrAB-TolC
MexAB-OprM
(E. coli
P. aeruginosa)
Reduced MIC of Cam, Nal,
Nor, and Spfx
Increased Cam uptake
Antibacterial
Synergism
Substrate accumulation
Mahamoud et al. (2011)
MBX2319 Synthetic
pyranopyridine
AcrB (E. coli) Decreased MIC of Cip, Lev,
and Prl
Docking
Time kill assay
Substrate accumulation
Effect on
outer-membrane
Effect on
inner-membrane
Vargiu et al. (2014),
Opperman et al. (2014)
2-substituted
benzothiazoles
Synthetic AdeABC
(Acinetobacter
baumannii)
Reduced MIC of cip Pharmacophore
hypothesis
Yilmaz et al. (2014)
Natural Compounds
EA-371α and EA-371δ Streptomyces
MF-EA-371-NS1
MexAB-OprM
(P. aeruginosa)
Reduce MIC of Lev Synergism
Substrate accumulation
Lee et al. (2001)
Geraniol Helichrysum italicum E. coli
P. aeruginosa
A. baumanii
Reduced MIC of β-lactams,
quinolones, and Cam
Antibacterial
Synergism
Lorenzi et al. (2009)
Plumbagin Plumbago indica AcrB (E. coli) Reduced MIC of Ery, Cam,
TPP, SDS, tet
Inhibition of Nile Red efflux
In silico screening
Antibacterial
Synergism
Non-substrate control
Inhibition of efflux
Effect on
outer-membrane
Ohene-Agyei et al.
(2014)
Nordihydroguaretic acid
(NDGA)
Creosote bush AcrB (E. coli) Reduced MIC of Ery, Cam,
Nov, Tet, and TPP
Shikonin Lithospermum
erythrorhizon
AcrB (E. coli) Reduced MIC of TPP
(−)-epigallocatechin
gallate EGCG
Green tea Campylobacter
spp.
Reduced MIC to Ery and
Cip
Antibacterial
Synergism
Kurincic et al. (2012)
Curcumin Curcuma longa
(Zingiberaceae)
P. aeruginosa Reduced MIC Mem, Carb,
Caz, Gen, and Cip
Antibacterial
Synergism
Negi et al. (2014)
(Continued)
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TABLE 1 | Continued
Compound Source Protein/
Organism
Actions1 Essays performed Reference
Lanatoside C and
diadzein
Phytochemical AcrB, MexB
(E. coli,
P. aeruginosa)
Reduced MIC of Lev and
Carb
Increased accumulation of
EtBr
High-throughput virtual
screening
Synergism
Substrate accumulation
Aparna et al. (2014)
4-hydroxy-α-tetralone Ammannia sp E. coli Reduced MIC of Tet RT-PCR study
In silico docking
Dwivedi et al. (2014)
Non-antibacterial drugs
Trimethoprim and
Epinephrine
Small heterocyclic or
nitrogen-containing
drugs
S. typhimurium
E. cloacae
S. marcescens
P. aeruginosa
K. pneumoniae
E. coli
Reduced MIC of Cip Antibacterial
Synergism
Substrate accumulation
Growth kinetics
Piddock et al. (2010)
Chlorpromazine,
Amitryptiline,
Trans-chlorprothixene
Non-antibiotic drugs P. aeruginosa Reduced MIC of Pen, Cxm,
and Tob
Antibacterial
Synergism
Kristiansen et al. (2010)
Sertraline Selective Serotonin
Re-uptake Inhibitors
AcrAB, AcrEF, MdtEF,
and MexAB
Inhibition of Nile Red efflux Inhibition of efflux
RT-PCR
Bohnert et al. (2011)
Artesunate Anti-malarial drug AcrAB-TolC (E. coli) Reduced MIC ofβ-lactam
antibiotic
Increased Dau uptake
Reduce mRNA expression
Antibacterial
Synergism
Substrate accumulation
RT-PCR
Li et al. (2011)
Pimozide Neuroleptic drug AcrAB-TolC (E. coli) Reduced MICs of Oxa and
EtBr
Inhibition of Nile rRed efflux
Synergism
Substrate efflux
Bohnert et al. (2013)
1Abbreviations used: Cam, Chloramphenicol; Carb , Carbanecillin; Caz , Ceftazidime; Cip , Ciprofloxacin; Clr , Clarithromycin; Cxm , Cefuroxime; Dau , Daunomycin;
Ery , Erythromycin; EtBr , Ethidium Bromide; Gen , Gentamicin; Lev , Levofloxacin; Mem , Meropenem; Nal , Nalidixic acid; Nor , Norfloxacin; Oxa , Oxacillin; Pen , Penicillin;
Prl , Piperacillin; Rif , Rifampicin; Spfx , Sparfloxacin; Tet , Tetracycline; Tob , Tobramycin; TPP , Triphenylphosphonium.
permeabilized the outer membrane (Lomovskaya et al., 2001).
Derivatives of PAβN with reduced toxicity, enhanced stability,
and better solubility were developed and advanced to the pre-
clinical stage, however, failed due to toxicity issues (Marquez,
2005; Lomovskaya et al., 2006; Lomovskaya and Zgurskaya, 2011;
Bhardwaj and Mohanty, 2012).
The structural basis for the inhibition of the RND trans-
porters has been recently described with the publication of
the crystal structures of AcrB from E. coli and MexB from
P. aeruginosa bound to a pyridopyrimidine derivative D13–
D900 (Nakashima et al., 2013). The inhibitor binding almost
overlapped with the binding of the substrates minocycline and
doxorubicin, while part of the inhibitor inserted into a nar-
row phenylalanine rich region in the deep binding pocket,
termed the hydrophobic trap by the authors. The authors
suggested that the inhibitor competitively inhibit substrate
binding and hinders the functional rotation of the eﬄux
pumps.
As there is only one structure of a RND protein bound to
an inhibitor published to date, docking, and molecular sim-
ulation studies were used to investigate the putative binding
modes of other inhibitors such as PAβN and NMP (Vargiu
et al., 2014) while in silico screening also provided informa-
tion on the binding of putative EPIs (Ohene-Agyei et al., 2014).
Both PAβN an NMP were predicted to interact with the switch
loop while D13–D9001and MBX2319 have more interactions
with the hydrophobic trap ﬁrst identiﬁed by Nakashima et al.
(2013).
Table 1 summarizes the compounds reported to act as EPIs
against Gram-negative organisms so far. The term EPI is used
loosely here as some of the included compounds were identi-
ﬁed based on their synergism with one or more antibiotic while
no further analysis was performed to study the mechanism of
inhibition or rule out non-speciﬁc eﬀects such as membrane
permeabilization.
Conclusion
There are various papers reporting the ability of crude extracts
from plants or other organisms to reduce antibiotic resistance
that were not dealt with in this review. As can be seen from
Table 1, there is also a sizable amount of pure compounds
which were able to synergise with antibiotics against drug resis-
tant Gram-negative bacteria. However, the translation of these
promising compounds into EPIs for clinical application is still
lacking. The most probable reason for the discrepancies in lead
compounds and ﬁnal outcome is the deﬁciency of follow through
from ﬁrst identiﬁcation of a compound with synergistic eﬀects
to identiﬁcation of true EPI activity and providing a thorough
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investigation into mechanism of action. With this review we
aimed to summarize the current knowledge of how drug eﬄux
can be inhibited.
The tools necessary to identify, test and characterize the mech-
anism of action of a putative EPI were also provided in order to
aid the discovery and development of EPIs with which we would
be able to stem the tide of multidrug resistant Gram-negative
infections.
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